Phase III IMmotion151 Study Showed Genentechs TECENTRIQ Atezolizumab and Avastin Bevacizumab Reduced the Risk of Disease Worsening or Death by 26 Percent in Certain People With Advanced Kidney Cancer

TECENTRIQ and Avastin met coprimary endpoint of investigatorassessed progressionfree survival PFS compared with sunitinib for people whose disease expressed PDL1 IMmotion151 is the second Phase III study to show positive P...